pirenzepine has been researched along with Cardiometabolic Syndrome in 1 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
Cardiometabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components not only include metabolic dysfunctions of METABOLIC SYNDROME but also HYPERTENSION, and ABDOMINAL OBESITY.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baptista, T | 1 |
| Beaulieu, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Placebo-Controlled, Cross-Over Trial of Aripiprazole Added to Obese Olanzapine-Treated Patients With Schizophrenia[NCT00351936] | Phase 4 | 16 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Evaluating change in Body Mass Index (BMI) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | kg/m^2 (Mean) |
|---|---|
| Aripiprazole | -0.4 |
| Placebo | 0.3 |
Evaluating change in fasting total cholesterol between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -3 |
| Placebo | 9 |
Evaluating change in high-density lipoprotein cholesterol (HDL-C) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | 0.4 |
| Placebo | 0.6 |
Evaluating change in low-density lipoprotein (LDL) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -0.2 |
| Placebo | 3.1 |
Evaluating change in triglyceride levels between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -51.7 |
| Placebo | 47.6 |
Evaluating change in waist-hip ratio (WHR) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | cm (Mean) |
|---|---|
| Aripiprazole | 0.0 |
| Placebo | 0.0 |
Evaluating change in weight (lbs) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | lbs (Mean) |
|---|---|
| Aripiprazole | -2.9 |
| Placebo | 2.1 |
1 other study available for pirenzepine and Cardiometabolic Syndrome
| Article | Year |
|---|---|
Body weight gain, insulin, and leptin in olanzapine-treated patients.
Topics: Antipsychotic Agents; Benzodiazepines; Body Weight; Female; Humans; Insulin; Leptin; Male; Metabolic | 2001 |